O. Eradiri

Comparison of diltiazem bioavailability from 3 marketed extended-release products for once-daily administration: implications of chronopharmacokinetics and dynamics.

K. Midha, O. Eradiri, 1997, International journal of clinical pharmacology and therapeutics.

Application of a stereospecific high-performance liquid chromatography assay to a pharmacokinetic study of etodolac enantiomers in humans.

F. Jamali, R. Mehvar, O. Eradiri, 1988, Journal of pharmaceutical sciences.

Pharmacokinetics of a Novel Diltiazem HCl Extended‐Release Tablet Formulation for Evening Administration

O. Eradiri, K. Albert, J. C. Lai, 2003, Journal of clinical pharmacology.

Use of Parent Drug and Metabolite Data in Bioavailability Assessment of a Novel Diltiazem HC1 Once-Daily Product

K. Midha, O. Eradiri, 1995, Pharmaceutical Research.

Single- and multiple-dose bioequivalence of two once-daily tramadol formulations using stereospecific analysis of tramadol and its demethylated (M1 and M5) metabolites

P. Silverstone, O. Eradiri, J. C. Lai, 2007, Current medical research and opinion.

Stereospecific high-performance liquid chromatographic analysis of tramadol and its O-demethylated (M1) and N,O-demethylated (M5) metabolites in human plasma.

R. Mehvar, O. Eradiri, R. Parasrampuria, 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy

Anuradha Ramamoorthy, Richard Pazdur, Kaushalkumar Dave, 2018, Clinical Cancer Research.

In Vitro Release Test Methods for Drug Formulations for Parenteral Applications

Erika S. Stippler, M. Hussain, J. Krämer, 2018 .